Fundraising FoxBiotech Startups
11,050 companies tagged Biotech, with their investors and founders.
0 investors
0 investors
0 investors
LifeCyte develops oral combination therapies that target chronic inflammation at the cellular level to slow the progression of age-related degenerative diseases such as macular degeneration, mild cognitive impairment, Alzheimer's, and traumatic brain injury. Its lead prototype, RestoViz, is aimed at age-related macular degeneration in older adults.
0 investors
Lifeward develops products for physical rehabilitation and recovery, aimed at improving function and daily-life health for people with conditions such as spinal cord injury, brain injury, stroke, and multiple sclerosis. Its offerings serve rehabilitation and orthopedic/sports medicine care settings.
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
Liminatus Pharma is a biotechnology company developing cancer immunotherapies, including a CD47 blockade program and multiple CAR-T cell therapy candidates. Its pipeline targets various tumor-associated antigens for oncology treatment.
0 investors
0 investors
Lion Biotechnologies develops and commercializes TIL (tumor infiltrating lymphocyte) cell therapies, individualized immunotherapies manufactured from patient T cells to treat solid tumor cancers, with its lead product Amtagvi approved for previously treated advanced melanoma and a pipeline of combination therapies and monotherapies for additional cancer types.
0 investors
0 investors
LIPAC Oncology is a pharmaceutical company developing chemotherapy treatments based on LiPax, a neoliposomal platform for local, targeted delivery of paclitaxel to treat intracavitary carcinomas. Its lead program targets non-muscle invasive bladder cancer, with additional indications in thoracic, upper tract urothelial, peritoneal, and ovarian cancers.
0 investors
Lipella Pharmaceuticals was a clinical-stage biotechnology company that developed therapies using a proprietary liposomal drug delivery platform, advancing candidates such as LP-10 and LP-310 through FDA-authorized Phase 2 trials in indications including oral lichen planus and hemorrhagic cystitis. The company ceased research and development activities in 2026 after a court-approved sale of its drug programs and intellectual property to XRAIY LLC, and the site now serves as a historical corporate archive.
0 investors
0 investors
0 investors
0 investors
0 investors
Lirum Therapeutics is a biopharmaceutical company that acquires, develops, and commercializes novel drug candidates for the treatment of difficult-to-treat, debilitating diseases. It was created by the former management team of Stemline Therapeutics.
0 investors
0 investors
0 investors
Lixte develops cancer therapies, focusing on precision oncology and clinical drug development. The company works on advancing innovative treatments in the oncology field.
0 investors